Are you living with an advanced or metastatic solid tumor? You may have an opportunity to participate in an upcoming Phase 2 clinical research study evaluating a potential new treatment.

The investigational treatment is an EGFR/PD-L1 bispecific antibody-drug conjugate (ADC) administered by intravenous infusion.

Who May Be Eligible?

• Participants may be considered if they:
• Have an advanced or metastatic solid tumor
• Have received at least one prior standard treatment
• Experienced disease progression, intolerance, or have no effective standard treatment options

Priority may be given to patients with non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC/EGJ SCC), or nasopharyngeal carcinoma (NPC).

Interested in learning more? Contact our research team to see if you may qualify.